Milestone Pharmaceuticals Reports Submission Of New Drug Application To FDA For Etripamil
Portfolio Pulse from Benzinga Newsdesk
Milestone Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for Etripamil.
October 24, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Milestone Pharmaceuticals' submission of a New Drug Application to the FDA for Etripamil could potentially boost the company's stock in the short term.
The submission of a New Drug Application is a significant step for any pharmaceutical company. If the FDA approves Etripamil, it could lead to increased revenues for Milestone Pharmaceuticals, which would likely have a positive impact on the company's stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100